Launched in 2020, C-TAP aims to facilitate timely, equitable and affordable access to Covid-19 health products by boosting their production and supply through open, non-exclusive licensing agreements
Expands AbbVie's neuroscience portfolio, adding first-in-class modulators of the synaptic vesicle protein 2A, including lead molecule SDI-118 currently in Phase 1b studies
ChipCytometry delivers single-cell targeted spatial proteomics for complex whole-tissue analysis of the tumour microenvironment, as well as deep immune profiling for applications in immunology, neuroscience, and infectious disease
Collaboration aims to capture patient-to-patient variability to determine the best treatment for every cancer
Covaxin is not approved in the USA for any age group
The CO2 Optimization module is one of the four modules (Product Costing, BoM Management, CO2 Optimization, Supplier Strategy) within the entire NDC Simulation Suite
Ten new Ayush hospitals and one Ayurvedic college will be set up in Nagaland and Mizoram
Meteoric Biopharmaceuticals have made rapid strides in the development of enzymes, probiotics and veterinary health products. It is seeking opportunities to scale up its growth backed by cutting edge R&D. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals spoke to Thomas C Thottathil on the way forward
Large players are adequately capitalised to make bigger investments to adjust for the ongoing fundamental shift in market opportunities
Ovarian cancer is one of the most difficult cancers to treat. It is typically not detected until later stages, and about 70 percent of patients will have recurrence after an initial treatment, which is often fatal
Subscribe To Our Newsletter & Stay Updated
